Skip to content

Efficacy and Safety of Photodynamic Therapy for CIN3

Efficacy and Safety of Photodynamic Therapy for Cervical Intraepithelial Neoplasia 3(CIN3):A Multicenter Prospective Cohort Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07009327
Enrollment
100
Registered
2025-06-06
Start date
2024-01-01
Completion date
2029-12-31
Last updated
2025-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Precancerous Cervical Lesion

Keywords

PDT, HPV, CIN 3

Brief summary

To investigate the efficacy and safety of photodynamic therapy (20% 5-amino-ketovalerate 630nm red light) in the treatment of cervical intraepithelial neoplasia 3(CIN 3)in women in the real world

Interventions

PROCEDUREALA-PDT

use ALA\_PDT to treat the disease

Sponsors

Peking University Third Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* CIN3, photodynamic therapy was required, * type 1 2 transformation area, colposcopy was sufficient * the lesion boundary was completely visible * The ECC did not indicate high-grade lesions

Exclusion criteria

* coexistence or suspicion of cancer; * TCT HSIL * involving glands * Porphyria patients, or suspected allergic to red and blue light. * severe medical comorbidities;

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of the treatment1 month after the treatmentcolposcopy and biopsy will be performed one month after the treatment. Patients will be categorised as having complete remission(CR) if biopsy confirmed LSIL. If CIN 2 was found after the first course of PDT, it would be categorised as partial remission(PR). Those with the same grade were categorised as persistent disease(PD). The proportion of CR after PDT treatment.

Countries

China

Contacts

Primary ContactQin Han
Lmlfe_lynn@126.com13810632686

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026